Stryker beats quarterly estimates on strong demand for medical devices

Zimmer Biomet Holdings

30/07/2026 22:38

Repeats to widen distribution with no changes to text
July 30 (Reuters) - U.S. medical device maker Stryker SYK.N on Thursday beat Wall Street estimates for second-quarter results, aided by strong demand for its implants and devices used in complex procedures ranging from spinal to orthopedic surgeries. 
However, the company's shares fell 9% in extended trading after the Michigan-based firm missed analysts' estimates for medical surgery and neurotechnology sales in the quarter, its largest revenue-generating segment.
     
Here are the details:
The company, which makes joint replacements and medical implants used to repair broken bones, narrowed its forecast for adjusted annual profit to between $14.95 and $15.10 per share, from its prior range of $14.90 to $15.10 per share.
Stryker's rivals in the orthopedics market include Zimmer Biomet ZBH.N and healthcare conglomerate Johnson & Johnson JNJ.N, where the companies jostle for market share across multiple segments such as hip and knee replacements, trauma and sports medicine.
Sales at Stryker's medical surgery and neurotechnology unit, rose 9.7% to $3.6 billion in the reported quarter, but missed analysts' estimates of $3.72 billion, according to data compiled by LSEG.
The orthopedics segment saw a 9.1% increase in sales to $3.0 billion, which beat analysts' expectations of $2.72 billion.
The company reported total revenue of $6.6 billion for the quarter, above analysts' expectations of $6.58 billion.
Stryker earned $3.69 per share for the quarter on an adjusted basis, surpassing estimates of $3.49 apiece.

 (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shailesh Kuber)
 ((Padmanabhan.Ananthan@thomsonreuters.com;))